Financial Report: Lilly

Lilly
1Q Revenues: $5.7 billion (+9%)
1Q Earnings: $1.2 billion (loss of $110.8 million 1Q17)  
Comments: New pharmaceutical products, including Trulicity, Cyramza, Basaglar, Jardiance, Taltz, Lartruvo, Olumiant, and Verzenio, represented 25% of total revenue and drove 11% volume growth. These products help offset declines in established brands including Cialis, down 7% to $495.4 million, Forteo, down 10% to $313.2 million, Cymbalta and Erbitux, both down 3% to $169.6 million and $149.6 million, respectively. Trulicity sales were up 82% to $678.3 million in the quarter. Cyramza sales were $183.6 million, up 7%. Basaglar sales were up 261% to $166 million. Jardiance sales were $151 million, up 104%. Taltz sales were $146.5 million, up 52%. Lartruvo sales were up 535 to 64.4 million. Newer products Olumiant and Verzenio sales were $32.2 million and $29.7 million, respectively.